Q32 Bio Inc. - Understand $qttb stock

$QTTB Market Cap: $297.8 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

-$49.69M

TTM

Current Assets

$93.90M

Q3 2024

Current Liabilities

$14.38M

Q3 2024

Current Ratio

652.84%

Q3 2024

Total Assets

$104.5M

Q3 2024

Total Liabilities

$86.25M

Q3 2024

Book Value

$18.30M

Q3 2024

Cash

$89.08M

Q3 2024

P/E

-5.993

Nov 29, 2024 EST

Free Cash Flow

-$77.93M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$1.156M	$3.208M	$33.97M	$2.702M	$1.666M	$3.684M	$0.00	$0.00
YoY Change	-63.97%	-90.56%	1157.25%	62.18%	-54.78%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	$1.156M	$3.208M	$33.97M	$2.702M	$1.666M	$3.684M	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Selling, General & Admin	$31.26M	$38.14M	$36.84M	$32.57M	$22.21M	$17.30M	$8.280M	$4.310M
YoY Change	-18.04%	3.54%	13.09%	46.65%	28.38%	108.94%	92.11%
% of Gross Profit
Research & Development	$62.00M	$98.35M	$93.09M	$100.4M	$89.40M	$47.95M	$21.38M	$5.700M
YoY Change	-36.96%	5.66%	-7.28%	12.3%	86.45%	124.27%	275.09%
% of Gross Profit
Depreciation & Amortization	$600.0K	$1.300M	$8.400M	$8.000M	$6.300M	$1.289M	$684.0K	$240.0K
YoY Change	-53.85%	-84.52%	5.0%	26.98%	388.75%	88.45%	185.0%
% of Gross Profit
Operating Expenses	$102.6M	$136.5M	$129.9M	$133.0M	$111.6M	$65.25M	$29.66M	$10.00M
YoY Change	-24.84%	5.06%	-2.29%	19.13%	71.05%	119.99%	196.6%
Operating Profit	-$101.4M	-$133.3M	-$95.95M	-$130.3M		-$59.93M
YoY Change	-23.93%	38.93%	-26.34%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Interest Expense	$5.582M	$3.230M	$185.0K	$1.570M	$6.030M	$4.350M	$540.0K	$20.00K
YoY Change	72.82%	1645.95%	-88.22%	-73.96%	38.62%	705.56%	2600.0%
% of Operating Profit
Other Income/Expense, Net	$14.35M	$134.5M	$185.0K	$1.569M	$6.027M	$4.349M	-$334.0K	$1.930M
YoY Change	-89.33%	72591.35%	-88.21%	-73.97%	38.58%	-1402.1%	-117.31%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Pretax Income	-$87.08M	$1.198M	-$95.76M	-$128.7M	-$103.9M	-$55.58M	-$29.99M	-$8.050M
YoY Change	-7368.78%	-101.25%	-25.59%	23.84%	86.97%	85.33%	272.55%
Income Tax	$0.00	$700.0K	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income		58.43%
Net Earnings	-$113.0M	-$5.005M	-$95.80M	-$128.7M	-$103.9M	-$55.58M	-$29.99M	-$8.050M
YoY Change	2156.96%	-94.78%	-25.56%	23.84%	86.98%	85.31%	272.56%
Net Earnings / Revenue	-9771.71%	-156.02%	-282.01%	-4762.92%	-6237.45%	-1508.6%
Basic Earnings Per Share	-$1.95	-$0.09	-$1.73
Diluted Earnings Per Share	-$1.95	-$0.09	-$1.732M	-$2.803M	-$2.467M	-$1.947M	-$798.9K	-$223.1K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Cash & Short-Term Investments	$82.65M	$175.0M	$155.9M	$217.4M	$262.4M	$214.7M	$129.7M	$11.40M
YoY Change	-52.78%	12.29%	-28.3%	-17.15%	22.22%	65.54%	1037.72%
Cash & Equivalents	$38.52M	$33.97M	$108.3M	$217.2M	$39.50M	$31.70M	$44.20M	$6.100M
Short-Term Investments	$43.39M	$141.0M	$47.49M	$0.00	$222.6M	$182.5M	$78.10M	$0.00
Other Short-Term Assets	$1.261M	$5.989M	$36.04M	$2.100M	$4.200M	$6.900M	$1.900M	$600.0K
YoY Change	-78.94%	-83.38%	1616.0%	-50.0%	-39.13%	263.16%	216.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$83.91M	$181.0M	$191.9M	$219.6M	$266.6M	$221.7M	$131.6M	$12.00M
YoY Change	-53.64%	-5.68%	-12.61%	-17.63%	20.25%	68.47%	996.67%
Property, Plant & Equipment	$650.0K	$21.64M	$17.86M	$42.90M	$42.70M	$35.60M	$3.200M	$2.000M
YoY Change	-97.0%	21.18%	-58.37%	0.47%	19.94%	1012.5%	60.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$25.81M
YoY Change	-100.0%
Other Assets		$0.00	$1.953M	$1.300M	$1.300M	$1.800M	$2.800M	$300.0K
YoY Change		-100.0%	50.23%	0.0%	-27.78%	-35.71%	833.33%
Total Long-Term Assets	$650.0K	$47.46M	$19.81M	$44.10M	$44.00M	$37.40M	$5.900M	$2.200M
YoY Change	-98.63%	139.53%	-55.07%	0.23%	17.65%	533.9%	168.18%
Total Assets	$84.56M	$228.5M	$211.7M	$263.7M	$310.6M	$259.1M	$137.5M	$14.20M
YoY Change
Accounts Payable	$3.234M	$1.144M	$2.366M	$4.700M	$2.600M	$15.70M	$2.500M	$900.0K
YoY Change	182.69%	-51.65%	-49.66%	80.77%	-83.44%	528.0%	177.78%
Accrued Expenses	$8.339M	$20.28M	$11.65M	$12.30M	$7.600M	$5.000M	$2.900M	$1.200M
YoY Change	-58.87%	74.01%	-5.27%	61.84%	52.0%	72.41%	141.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.57M	$22.58M	$17.23M	$22.70M	$12.40M	$22.50M	$8.900M	$6.400M
YoY Change	-48.74%	31.06%	-24.11%	83.06%	-44.89%	152.81%	39.06%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$27.92M	$24.84M	$45.10M	$39.70M	$40.20M	$30.40M	$300.0K
YoY Change	-100.0%	12.37%	-44.91%	13.6%	-1.24%	32.24%	10033.33%
Total Long-Term Liabilities	$0.00	$27.92M	$24.84M	$45.10M	$39.70M	$40.20M	$30.40M	$300.0K
YoY Change	-100.0%	12.37%	-44.91%	13.6%	-1.24%	32.24%	10033.33%
Total Liabilities	$11.57M	$50.49M	$42.07M	$67.70M	$52.10M	$62.70M	$39.20M	$6.700M
YoY Change	-77.08%	20.02%	-37.86%	29.94%	-16.91%	59.95%	485.07%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	57.83M	57.40M	55.28M
Diluted Shares Outstanding	57.83M	57.40M	55.28M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $297.82 Million

About Q32 Bio Inc.

Q32 Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 42 full-time employees. The company went IPO on 2018-03-28. Q32 Bio Inc. is a clinical-stage biotechnology company. The firm is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. The company is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The firm has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.

Industry: Pharmaceutical Preparations Peers: Adverum Biotechnologies, Inc. BIOXYTRAN, INC Checkpoint Therapeutics, Inc. LEAP THERAPEUTICS, INC. Climb Bio, Inc. GALECTIN THERAPEUTICS INC HCW Biologics Inc. Longeveron Inc. SPECTRUM PHARMACEUTICALS INC